Outbreak risks, cases, and costs of vaccination strategies against wild poliomyelitis in polio-free settings: a modelling study
Auzenbergs, M.; Abbas, K.; Voorman, A.; Peak, C.; Jit, M.; O'Reilly, K. M.
Show abstract
BackgroundPolio eradication was threatened in 2022 by importation of wild poliovirus serotype 1 into Malawi with subsequent international spread, representing the first wild polio cases in Africa since 2014. Preventing importations and spread of wild poliovirus is critical, and dependent on population immunity provided through routine immunisation and supplementary immunisation activities (SIAs). However, the scale of preventative SIAs has reduced in recent years due to financial constraints. MethodsWe developed a mathematical model of polio transmission dynamics to evaluate the probability of an outbreak, expected number of poliomyelitis cases, and the costs associated with vaccination delivery through routine immunisation (RI), outbreak response SIAs (oSIAs) and preventative SIAs (pSIAs). Across varying levels of routine immunisation coverage, we explore three key strategies: RI+oSIAs, RI+oSIAs+annual pSIAs, and RI+oSIAs+biannual pSIAs. ResultsThe annual pSIA strategy (RI+oSIAs+annual pSIAs) had higher costs but greater probability of no outbreaks: under our model assumptions, annual pSIAs result in 80% probability of no outbreaks when routine immunisation coverage [≥]50%. The biannual pSIA strategy (RI+oSIAs+biannual pSIAs) costs less and averts more outbreaks than RI+oSIAs, but RI coverage [≥]65% was required to achieve equivalent risk of no outbreaks. The strategy with no pSIAs (RI+oSIAs) had the lowest costs but required [≥]75% RI coverage to achieve equivalent risk of no outbreaks. ConclusionPrioritisation of pSIAs must balance outbreak risk against implementation costs, ideally favouring the smallest manageable outbreak risk compatible with elimination. We infer that there are few short-term risks due to population immunity from RI, but without pSIAs, long-term risks accumulate and can result in outbreaks with potential for international spread. We do not consider the costs of further delaying the eradication timeline or societal implications of outbreaks, both of which emphasise the need for pSIAs.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cost-effectiveness Analysis of Alternative Infant and Neonatal Rotavirus Vaccination Schedules in Malawi 96%
- Rural prioritization may increase the impact of COVID-19 vaccines in Sub-Saharan Africa due to ongoing internal migration: A modeling study 95%
- Assessing yellow fever outbreak potential and implications for vaccine strategy 94%
Similar papers in this journal
- Estimating the global demand curve for a leishmaniasis vaccine: a generalisable approach based on global burden of disease estimates 95%
- Estimation of Lassa fever incidence rates in West Africa: development of a modeling framework to inform vaccine trial design 94%
- Real-time projections of epidemic transmission and estimation of vaccination impact during an Ebola virus disease outbreak in the Eastern region of the Democratic Republic of Congo 93%
Similar papers in this journal
- COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery 95%
- Potential Antenatal Care-Mediated Benefits of Delivering Maternal Immunization in Five Low- and Middle-Income Countries: A Modeling Analysis 94%
- Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria 93%
Similar papers in this journal
- When time-dependence in disease outcome risk is not captured by impact evaluation modeling studies: a measles vaccination case study 95%
- Potential health and economic impact of paediatric vaccination using next generation influenza vaccines in Kenya: a modelling study 94%
- Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa 93%
Similar papers in this journal
- Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: a modelling study 95%
- Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria 94%
- Critical success factors for routine immunization performance: A case study of Zambia 2000 to 2018 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.